PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from Taiwan

Selling into Europe as a biologics and biosimilars maker from Taiwan

Your team files a European dossier that clears validation and launches on schedule.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Taiwan, Biologics and biosimilarswho it is written for

Why this training matters

The European Medicines Agency raises a major objection to your biosimilar application: the comparative data is incomplete. The clock stops while your team in Taipei rebuilds the file. A competitor takes the hospital tender you planned for, and your launch slips by months.

What changes after this course

Your team files dossiers that answer the assessor's questions before they are asked. Sales and market access agree on biosimilar messaging and reimbursement rules before the first call. You hold a certificate per learner and a per-person training record for the next inspection.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory team stops guessing what assessors want. They lay out the Common Technical Document to the European format, put the comparative quality data in Module 3 where reviewers look for it, and cite Directive 2001/83/EC and the European Medicines Agency biosimilar guideline in the right places. The application reaches validation without a request for another trial.

In quality assurance, an inspector's question no longer means a search through folders. Your managers adapt procedures to EudraLex Volume 4, Part I and Annex 2 without piling on paperwork, and floor staff answer in their own words. The inspection shows a biologics site that already works to European Union Good Manufacturing Practice.

Safety work starts before the first sale. Your pharmacovigilance staff set up the system Regulation (EU) No 1235/2010 requires, with a Qualified Person for Pharmacovigilance based in the European Economic Area and periodic safety update reports filed on time. A colleague who hears of an adverse event knows what to pass on, to whom, and how fast.

Sales directors pitch hospital pharmacists with equivalence data, not a discount sheet. They keep to the European Federation of Pharmaceutical Industries and Associations Code of Practice and the national disclosure rules, and they know when a Supplementary Protection Certificate stops a launch. Your export certificates from the Taiwan Food and Drug Administration are ready before the buyer asks.

Who needs this training

  • Regulatory Affairs Manager

    They map Taiwanese records into the Common Technical Document and know one gap in Module 3 can stop the clock. This course shows where assessors look and what answers them first.

  • Quality Assurance Lead for Biologics

    They face a European inspection and must show that procedures match EudraLex Volume 4 and Annex 2, with staff who can explain them without notes.

  • Sales Director, Europe Expansion

    They prepare for the first meeting with a German hospital pharmacist and need biosimilar messaging built on equivalence evidence, within the code of practice and the disclosure rules.

  • Market Access Specialist

    They must propose a first price before they know how national bodies assess biosimilars, and need the reimbursement logic ahead of the negotiation, not after it.

  • Pharmacovigilance Manager

    They must stand up a safety system for a European marketing authorisation, with the Qualified Person for Pharmacovigilance and the reporting duties named in writing before the first shipment.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: Taiwan

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Lay out a Common Technical Document dossier with Module 3 quality data placed where European Medicines Agency reviewers expect it.
  2. Revise your procedures against EudraLex Volume 4, Part I and Annex 2, and mark which ones need no change.
  3. Name the Qualified Person for Pharmacovigilance and list the reporting duties that Regulation (EU) No 1235/2010 places on the Marketing Authorisation Holder.
  4. Draft a biosimilar message for hospital pharmacists that rests on equivalence evidence instead of a price-only pitch.
  5. Request a Certificate of Pharmaceutical Product from the Taiwan Food and Drug Administration and check export papers before shipment.
  6. Check an originator's patent family and Supplementary Protection Certificate to set the earliest lawful entry date.
  7. Record transfers of value to physicians in line with the disclosure rules of each country you sell in.

What the company gets

  • Your marketing application reaches the European Medicines Agency with the comparative data in the right place, so fewer weeks are lost to clock stops.
  • Your quality managers meet a European Union Good Manufacturing Practice inspection with documents ready and staff who can answer for them.
  • Your sales team enters hospital tenders with science-based biosimilar messaging that already fits the code of practice and the disclosure rules.
  • Your export certificates and cold chain contracts are settled before the first shipment, so stock does not wait at customs.
  • Each learner holds a certificate, and you hold a per-person training record to show an inspector or auditor.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Size the European biologics market and choose your first launch countries

    • Why one European launch plan fails, and how to split the continent into markets that buy differently.
    • How to size the German biosimilar market from public data before you hire a single representative.
    • The shortlist of first markets your board can defend, drawn from who buys, who pays and who prescribes.
  2. 2Apply European Medicines Agency rules for biologics and biosimilars

    • Why the centralised procedure with the European Medicines Agency is mandatory for your biologic.
    • What Article 10(4) of Directive 2001/83/EC makes you prove about similarity, in plain terms.
    • How to plan the comparability exercise so assessors see similarity and do not ask for another trial.
  3. 3Get Taiwan export papers and certificates in order before the first shipment

    • How to request a Certificate of Pharmaceutical Product in Taiwan before a buyer asks for it.
    • Where your Taiwan manufacturing licence helps with European inspectors, and where it stops.
    • What to check on export paperwork so a shipment is not held at customs while the cold chain runs down.
  4. 4Meet EudraLex Volume 4 and Annex 2 before the inspector arrives

    • Which EudraLex Volume 4, Part I chapters shape the questions an inspector asks on a biologics line.
    • How Annex 2 changes your procedures for biological medicinal products, and which ones stay as they are.
    • How to brief your floor staff so they answer an inspector's question in one clear sentence.
  5. 5Prepare the quality system and Common Technical Document dossier for review

    • How to lay out the Common Technical Document so your application passes the first validation check.
    • How to write Module 3 so the reviewer finds each quality answer without sending a question back.
    • The quality system records that prove your batches match the product described in the dossier.
  6. 6Run pharmacovigilance under Regulation (EU) No 1235/2010 from day one

    • What Regulation (EU) No 1235/2010 requires of your safety system before the first vial ships.
    • Why your Qualified Person for Pharmacovigilance must be based in the European Economic Area.
    • What to do when an adverse event report lands with a colleague who does not know the reporting clock.
  7. 7Clear patents and Supplementary Protection Certificates before launch

    • How to read an originator's patent family and find the date your biosimilar may enter.
    • When a Supplementary Protection Certificate delays your entry, and when it does not.
    • Why launching at risk before expiry can bring an injunction, and how to avoid the order.
  8. 8Win pricing and reimbursement in each national market

    • What German payers and the statutory health insurers look at when they set access terms for a biosimilar.
    • How to prepare the pricing file before reimbursement talks so the first offer is not a low price cap.
    • When to enter national pricing talks early, and when to wait for the first competitor's price.
  9. 9Build a European sales and distribution network that holds the cold chain

    • How to choose a distributor with a wholesale distribution authorisation and a Responsible Person.
    • What the Falsified Medicines Directive demands on prescription packs, and who in your chain must check them.
    • The cold chain terms to write into a distribution contract so a temperature excursion has a named owner.
  10. 10Draft biosimilar messages that prescribers and pharmacists trust

    • How to show biosimilarity to a hospital pharmacist without sounding like you sell a generic.
    • The biosimilarity arguments that skeptical prescribers accept, and the ones that lose the room.
    • Why leading with price puts your safety profile in doubt, and what to say first.
  11. 11Keep every sales contact within the industry code and disclosure rules

    • What the European Federation of Pharmaceutical Industries and Associations code allows on a doctor visit.
    • How transfers of value to physicians are recorded and disclosed, even the meal you thought was minor.
    • What the United Kingdom Bribery Act 2010 means for your sales incentives and local agents.
  12. 12Launch in Germany, France and the United Kingdom in the right order

    • How to sequence Germany, France and the United Kingdom so early supply is never stretched.
    • The hospital tender steps your team must complete to be on the list when the contract is awarded.
    • What to track after launch so expiring stock and missed targets show up while you can still act.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Taiwan, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team